Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,702 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment.
Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller C, Burger J, Lerner S, Kantarjian H, Keating M. Wierda WG, et al. Among authors: burger j. J Clin Oncol. 2009 Apr 1;27(10):1637-43. doi: 10.1200/JCO.2008.18.1701. Epub 2009 Feb 17. J Clin Oncol. 2009. PMID: 19224852 Free PMC article.
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
Jabbour E, Jones D, Kantarjian HM, O'Brien S, Tam C, Koller C, Burger JA, Borthakur G, Wierda WG, Cortes J. Jabbour E, et al. Among authors: burger ja. Blood. 2009 Sep 3;114(10):2037-43. doi: 10.1182/blood-2009-01-197715. Epub 2009 Jun 30. Blood. 2009. PMID: 19567878 Free PMC article.
Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).
Alatrash G, Albitar M, O'Brien S, Wang X, Manshouri T, Faderl S, Ferrajoli A, Burger J, Garcia-Manero G, Kantarjian HM, Lerner S, Keating MJ, Wierda WG. Alatrash G, et al. Among authors: burger j. Br J Haematol. 2010 Feb;148(3):386-93. doi: 10.1111/j.1365-2141.2009.07965.x. Epub 2009 Nov 6. Br J Haematol. 2010. PMID: 19895616 Free PMC article. Clinical Trial.
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.
Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R, Dara S, Jorgensen J, Kebriaei P, Champlin R, Borthakur G, Burger J, Ferrajoli A, Garcia-Manero G, Wierda W, Cortes J, Kantarjian H. Ravandi F, et al. Among authors: burger j. Blood. 2010 Sep 23;116(12):2070-7. doi: 10.1182/blood-2009-12-261586. Epub 2010 May 13. Blood. 2010. PMID: 20466853 Free PMC article. Clinical Trial.
1,702 results